Published in Brain, Behavior and Immunity—is the first to suggest that a tumor-driving gene known as AEG-1 actively regulates the inflammation responsible for causing chemotherapy-induced peripheral neuropathy (CIPN), a common and painful side effect of cancer treatment. Eliminating the function of this gene using targeted therapies could become a critical strategy for managing a debilitating side effect experienced by many cancer patients.
This article was originally published on MedicalXpress.com
